[go: up one dir, main page]

PE20140675A1 - CONTROLLED RELEASE PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION - Google Patents

CONTROLLED RELEASE PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION

Info

Publication number
PE20140675A1
PE20140675A1 PE2013001406A PE2013001406A PE20140675A1 PE 20140675 A1 PE20140675 A1 PE 20140675A1 PE 2013001406 A PE2013001406 A PE 2013001406A PE 2013001406 A PE2013001406 A PE 2013001406A PE 20140675 A1 PE20140675 A1 PE 20140675A1
Authority
PE
Peru
Prior art keywords
polymer
oral administration
controlled release
release pharmaceutical
pharmaceutical tablet
Prior art date
Application number
PE2013001406A
Other languages
Spanish (es)
Inventor
Arroyo Hector Senosiain
Paniagua Maria Angelica Arzola
Hernandez Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of PE20140675A1 publication Critical patent/PE20140675A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPRIMIDO DE LIBERACION CONTROLADA NO HINCHABLE DE ADMINISTRACION ORAL CARACTERIZADO PORQUE EL PRINCIPIO ACTIVO SE ENCUENTRA EN UN SISTEMA MATRICIAL POLIMERICO EROSIONABLE Y DE LIBERACION POR DIFUSION FORMADO POR UN POLIMERO RETARDANTE Y UN POLIMERO FORMADOR DE MATRIZ, DONDE EL PRINCIPIO ACTIVO ES ENOXACINO, OFLOXACINO, CIPROFLOXACINO CLORHIDRATO, CIPROFLOXACINO BASE, LEVOFLOXACINO, ENTRE OTROS; EL POLIMERO RETARDANTE ES ETILCELULOSA, ACETATO DE CELULOSA, METILCELULOSA, ENTRE OTROS Y EL POLIMERO FORMADOR DE MATRIZ SE SELECCIONA DE HIDROXIPROPILMETILCELULOSA, HIDROXIETILCELULOSA, HIDROMETILCELULOSA Y METILCELULOSAREFERRED TO A NON-INFLATABLE CONTROLLED RELEASE TABLET FOR ORAL ADMINISTRATION CHARACTERIZED BECAUSE THE ACTIVE PRINCIPLE IS FOUND IN AN EROSIONABLE AND DIFFUSION-RELEASED POLYMERIC MATRIX SYSTEM FORMED BY A RETARDINOUS POLYMER, AND A DIFFUSION-FORMING PRINCIPAL POLYMER , CIPROFLOXACINO HYDROCHLORIDE, CIPROFLOXACIN BASE, LEVOFLOXACIN, AMONG OTHERS; THE RETARDANT POLYMER IS ETILCELLULOSE, CELLULOSE ACETATE, METHYLCELLULOSE, AMONG OTHERS AND THE MATRIX FORMING POLYMER IS SELECTED FROM HYDROXYPROPYLMETILCELLULOSE, HYDROXYETHYLCELLULOSE, HYDROXYETHYLCELLULOSE AND METILCELLULOSA

PE2013001406A 2010-12-17 2011-12-16 CONTROLLED RELEASE PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION PE20140675A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (en) 2010-12-17 2010-12-17 Controlled-release pharmaceutical tablet for oral administration.

Publications (1)

Publication Number Publication Date
PE20140675A1 true PE20140675A1 (en) 2014-06-25

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001406A PE20140675A1 (en) 2010-12-17 2011-12-16 CONTROLLED RELEASE PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION

Country Status (11)

Country Link
BR (1) BR112013014963A2 (en)
CL (1) CL2013001707A1 (en)
CO (1) CO6721021A2 (en)
CR (1) CR20130288A (en)
DO (1) DOP2013000136A (en)
EC (1) ECSP13012766A (en)
GT (1) GT201300154A (en)
MX (1) MX2010014153A (en)
PE (1) PE20140675A1 (en)
RU (1) RU2603469C2 (en)
WO (1) WO2012080984A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2002358270A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same

Also Published As

Publication number Publication date
WO2012080984A2 (en) 2012-06-21
CL2013001707A1 (en) 2014-01-10
CO6721021A2 (en) 2013-07-31
RU2013127408A (en) 2015-01-27
MX2010014153A (en) 2012-06-18
BR112013014963A2 (en) 2016-09-13
RU2603469C2 (en) 2016-11-27
CR20130288A (en) 2013-08-13
GT201300154A (en) 2014-05-07
WO2012080984A3 (en) 2012-08-16
DOP2013000136A (en) 2013-10-15
ECSP13012766A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
EP2246052A4 (en) RAPID DISINTEGRATION ORAL ADMINISTRATION TABLET CONTAINING IMIDAFENACIN
NZ605352A (en) Process for producing glycosaminoglycans
GT200600445A (en) SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF THE ACTIVE PRINCIPLE.
LTPA2019508I1 (en) Drug delivery system for the delivery of hard-water-soluble, pharmaceutically active substances
CY1118032T1 (en) PROCESSES FOR COMMERCIAL PREPARATION OF PHARMACEUTICAL ACTIVE AGENT
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
CL2013003161A1 (en) Pharmaceutical composition in the form of rapidly dissolving microgranules for vaginal administration comprising a) a vaginally active drug, b) a polymeric excipient, c) a sugar alcohol, saccharide or a mixture thereof; preparation procedure
MX2013001985A (en) Nalbuphine-based formulations and uses thereof
JO3112B1 (en) A fast dissolving pharmaceutical composition
BR112013029199A2 (en) drug delivery system, two drug delivery device, method for preparing the same, tablet for sublingual administration of an active ingredient, and method for administering an active ingredient to an individual
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
CR20140358A (en) DRUG ADMINISTRATION SYSTEM
EA201291104A1 (en) ORAL MEDICINAL FORMS BENDAMUSTIN
IT1401284B1 (en) NEW PHARMACEUTICAL FORMULATIONS SUITABLE FOR ORAL ADMINISTRATION OF DIHYDRATE ESOMEPRAZOLE MAGNESIUM, IN THE FORM OF MUPS TABLETS (MULTI UNIT PELLETS SYSTEM).
PE20140675A1 (en) CONTROLLED RELEASE PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION
CO6390098A2 (en) PRE-COMPACTED QUICK DISINTEGRATION FORMULATIONS OF COMPOUNDS WITH LOW ORAL BIOD AVAILABILITY.
MX2012007393A (en) Fast dissolving pharmaceutical composition comprising lornoxicam.
UY35324A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DEXKETOPROPHENE AND TRAMADOL
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
TR201005911A2 (en) A drug formulation with improved dissolution profile.
EA201992463A1 (en) DRUG DELIVERY SYSTEM
ES2422657A1 (en) Solid cilostazol pharmaceutical composition
GR1008082B (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof

Legal Events

Date Code Title Description
FG Grant, registration